Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-1719PMID 18483356PMCID PMC2430468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma

  2007cited by this paper
• Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

  2006cited by this paper
• Targeted Modulation of MGMT: Clinical Implications

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cited by this paper
• First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

  2006cited by this paper
• A phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

  2006cited by this paper
• O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

  2006cited by this paper
• Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours.

  2006cited by this paper
• Poly(ADP-ribose)polymerase inhibition - where now?

  2005cited by this paper
• First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

  2005cited by this paper
• PARP inhibitors for cancer therapy

  2005cited by this paper
• Cellular and molecular mechanisms that underlie Entamoeba histolytica pathogenesis: prospects for intervention

  2005cited by this paper
• Chemopotentiation by PARP inhibitors in cancer therapy.

  2005cited by this paper
• Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

  2004cited by this paper
• Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

  2004cited by this paper
• Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions

  2004cited by this paper
• Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

  2004cited by this paper
• Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

  2004cited by this paper
• Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.

  2004cited by this paper
• Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.

  2003cited by this paper
• Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.

  2003cited by this paper
• Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

  2003cited by this paper
• Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

  2003cited by this paper
• A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase

  2003cited by this paper
• Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

  2003cited by this paper
• Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

  2003cited by this paper
• Mechanisms of human DNA repair: an update.

  2003cited by this paper
• Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

  2002cited by this paper
• Model systems in neurooncology.

  2002cited by this paper
• Temozolomide: a novel oral alkylating agent

  2001cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• A Mouse Model for Glioma: Biology, Pathology, and Therapeutic Opportunities

  2000cited by this paper
• Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.

  2000cited by this paper
• Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.

  2000cited by this paper
• Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

  2000cited by this paper
• Cancer multidrug resistance

  1999cited by this paper
• Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

  1999cited by this paper
• DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.

  1999cited by this paper
• Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

  1999cited by this paper
• Relationship Between O6-methylguanine-DNA Methyltransferase Levels and Clinical Response Induced by Chloroethylnitrosourea Therapy in Glioma Patients

  1999cited by this paper
• Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

  1998cited by this paper
• The role of DNA mismatch repair in drug resistance.

  1998cited by this paper
• Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

  1998cited by this paper
• Survival of Patients with Glioblastoma Multiforme is not Influenced by Altered Expression of P16, P53, EGFR, MDM2 or Bcl‐2 Genes

  1998cited by this paper
• The role of DNA mismatch repair in drug resistance

  1998cited by this paper
• Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

  1998cited by this paper
• DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

  1998cited by this paper
• Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme

  1997cited by this paper
• O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.

  1997cited by this paper
• In vitro and in vivo models for the study of brain tumour invasion.

  1997cited by this paper
• bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status

  1997influential reference
• Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

  1997cited by this paper
• O6-benzylguanine and its role in chemotherapy.

  1997cited by this paper
• Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

  1997cited by this paper
• Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.

  1996cited by this paper
• Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

  1996cited by this paper
• O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

  1996cited by this paper
• Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase

  1996cited by this paper
• 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

  1996cited by this paper
• p53--integrating the complexity.

  1996influential reference
• Genomic instability and tolerance to alkylating agents.

  1996cited by this paper
• A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

  1996cited by this paper
• Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.

  1996cited by this paper
• EDITORIAL. p53—INTEGRATING THE COMPLEXITY

  1996cited by this paper
• Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

  1996cited by this paper
• Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.

  1995cited by this paper
• Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells.

  1995cited by this paper
• Activity of temozolomide in the treatment of central nervous system tumor xenografts.

  1995cited by this paper
• Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells.

  1994cited by this paper
• p53 mutations increase resistance to ionizing radiation.

  1993cited by this paper
• Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

  1993cited by this paper
• Repair of DNA containing O6‐alkylguanine

  1992cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Self-destruction and tolerance in resistance of mammalian cells to alkylation damage.

  1992cited by this paper
• O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.

  1992cited by this paper
• Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

  1991cited by this paper
• Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

  1990cited by this paper
• Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

  1990cited by this paper
• DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.

  1987cited by this paper
• Intracerebral transplantation of a human glioma line in immunosuppressed rats.

  1984cited by this paper

• Roles of base and nucleotide excision repair activities in cancer treatment: implications for prognosis and resistance to therapy in breast and colorectal cancers.

  2026cites this paper
• Novel imidazotetrazine derivatives overcome temozolomide resistance in glioblastoma by inducing ferroptosis and apoptosis

  2026cites this paper
• Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy

  2025cites this paper
• Preparation, structural characterization, and pharmacological applications of polysaccharides from the genus Aconitum: A review.

  2025cites this paper
• Valproic Acid Reduces Invasiveness and Cellular Growth in 2D and 3D Glioblastoma Cell Lines

  2025cites this paper
• Enhanced Glioblastoma Treatment via Carbon-coated Perovskite Nanohybrid: Synergistic Effects of Targeted Chemotherapy and Magnetic Hyperthermia

  2025cites this paper
• Artificial Intelligence in the Diagnosis and Treatment of Brain Gliomas

  2025cites this paper
• Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines

  2025cites this paper
• Discovery of a novel Wnt inhibitor DK419: Reversing temozolomide resistance in glioblastoma by switching off Wnt/β-catenin signaling pathway to inhibit MGMT expression.

  2025cites this paper
• GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine

  2025cites this paper
• Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype—Is There Really a Worse One?

  2025cites this paper
• Targeting cell cycle checkpoints for glioma therapy.

  2025cites this paper
• A Phenotype-Driven Multi-Omic Atlas of Glioblastoma Invasion

  2025cites this paper
• Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma

  2025cites this paper
• Prognostic Role of Invasion-Related Extracellular Matrix Molecules in Diffusely Infiltrating Grade 2 and 3 Astrocytomas

  2024cites this paper
• Revisiting Temozolomide's role in solid tumors: Old is gold?

  2024cites this paper
• Assessment of MGMT and TERT Subtypes and Prognosis of Glioblastoma by Whole Tumor Apparent Diffusion Coefficient Histogram Analysis

  2024cites this paper
• Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

  2024cites this paper
• Understanding glioblastoma stromal barriers against NK cell attack using tri-culture 3D spheroid model

  2024cites this paper
• Let-7a-3p overexpression increases chemosensitivity to carmustine and synergistically promotes autophagy and suppresses cell survival in U87MG glioblastoma cancer cells

  2024cites this paper
• Quantum chemical exploration of B2C2N2 nanosheet as anticancer drug delivery substrate

  2024cites this paper
• Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma

  2024cites this paper
• IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma

  2024cites this paper
• Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT-methylated glioblastoma

  2024cites this paper
• MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

  2024cites this paper
• Borneol-modified docetaxel plus tetrandrine micelles for treatment of drug-resistant brain glioma

  2024cites this paper
• AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma

  2024cites this paper
• Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance

  2023cites this paper
• Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma

  2023cites this paper
• Expert opinion on translational research for advanced glioblastoma treatment

  2023cites this paper
• Glioblastoma-on-a-chip construction and therapeutic applications

  2023cites this paper
• Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents

  2023cites this paper
• Abrogation of the G2/M checkpoint as a chemo sensitization approach for alkylating agents.

  2023cites this paper
• Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma

  2023cites this paper
• Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.

  2023influential citation
• Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells

  2023cites this paper
• RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance.

  2023cites this paper
• NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells

  2022cites this paper
• Differential role of Pax6 and its interaction with Shh–Gli1–IDH2 axis in regulation of glioma growth and chemoresistance

  2022cites this paper
• A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.

  2022cites this paper
• Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation

  2022cites this paper
• Polysialic Acid Sustains the Hypoxia-Induced Migration and Undifferentiated State of Human Glioblastoma Cells

  2022cites this paper
• Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma

  2022cites this paper
• Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review.

  2022cites this paper
• Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma.

  2022cites this paper
• Nitrogen Mustard: a Promising Class of Anti-Cancer Chemotherapeutics – a Review

  2022cites this paper
• Hedgehog signaling regulates the development and treatment of glioblastoma

  2022cites this paper
• Non-coding RNAs enhance the apoptosis efficacy of therapeutic agents used for the treatment of glioblastoma multiform

  2022cites this paper
• Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles

  2022cites this paper
• RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.

  2022cites this paper
• A Tumor Suppressor Gene, N-myc Downstream-Regulated Gene 1 (NDRG1), in Gliomas and Glioblastomas

  2022cites this paper
• Triple branched RGD modification on liposomes: A prospective strategy to enhance the glioma targeting efficiency.

  2022cites this paper
• Tumour‐associated CD204+ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin‐6‐enriched inflammatory profile in glioblastoma

  2021cites this paper
• CAF promotes chemoresistance through NRP2 in gastric cancer

  2021cites this paper
• Molecular mechanisms in temozolomide-resistant glioblastoma

  2021cites this paper
• A New Perspective on Cancer Therapy: Changing the Treaded Path?

  2021cites this paper
• Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance

  2021cites this paper
• Chemoresistance mechanisms in mouse models of glioblastoma

  2021cites this paper
• Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.

  2021cites this paper
• Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival

  2021cites this paper
• Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy

  2021cites this paper
• Antineoplastics Encapsulated in Nanostructured Lipid Carriers

  2021cites this paper
• Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance

  2021cites this paper
• The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

  2021cites this paper
• Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma

  2021cites this paper
• The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model

  2021cites this paper
• Natural Compounds in Glioblastoma Therapy: Preclinical Insights, Mechanistic Pathways, and Outlook

  2021cites this paper
• Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System

  2021cites this paper
• Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the MGMT Gene Expression in Human Glioblastoma Cells

  2021cites this paper
• DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies

  2021cites this paper
• Genotoxic therapy and resistance mechanism in gliomas.

  2021cites this paper
• Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?

  2021cites this paper
• Evolution of Nitrogen-Based Alkylating Anticancer Agents

  2021cites this paper
• BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort

  2021cites this paper
• The influence of methylation status on a stochastic model of MGMT dynamics in glioblastoma: phenotypic selection can occur with and without a downshift in promoter methylation status.

  2021cites this paper
• Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives

  2021cites this paper
• [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].

  2021cites this paper
• CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging

  2021cites this paper
• Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems

  2021cites this paper
• Antioxidant responses related to temozolomide resistance in glioblastoma.

  2021cites this paper
• The complexity and regulation of repair of alkylation damage to nucleic acids

  2021cites this paper
• Development of a multi-functional preclinical device for the treatment of glioblastoma.

  2021cites this paper
• Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound

  2021cites this paper
• Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma

  2020cites this paper
• Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

  2020cites this paper
• The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas

  2020cites this paper
• Non-Coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development—Their Diagnostic and Therapeutic Potential

  2020cites this paper
• Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness

  2020cites this paper
• TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT

  2020cites this paper
• Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

  2020influential citation
• Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

  2020cites this paper
• Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

  2020cites this paper
• The emerging role of cold atmospheric plasma in glioblastoma therapy

  2020cites this paper
• Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.

  2020cites this paper
• Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation

  2020cites this paper
• The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

  2020cites this paper
• Enterovirus A71 Oncolysis of Malignant Gliomas.

  2020cites this paper
• Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma

  2020cites this paper
• Untying the Gordian Knot : Why Glioblastomas are Still Incurable, and How Can We overcome the Hurdles

  2020cites this paper
• MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR

  2020cites this paper